Northera

Entity type image
Type: Product
Name: Northera
First reported May 22 2013 - Updated May 23 2013 - 3 reports
Deutsche Bank AG
Deutsche Bank AG

Chelsea Therapeutics to Present at the 38th Annual Deutsche Bank Health Care Conference GlobeNewswire

(GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (CHTP) is scheduled to present at the 38th Annual Deutsche Bank Health Care Conference at 4:50 PM on Wednesday, May 29, 2013 in Boston.Nick Riehle, Vice President Administration and Chief Financial ... [Published Yahoo! Finance - May 22 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

Chelsea Therapeutics Reports First Quarter 2013 Financial Results

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the first quarter ended March 31, 2013. "In the first quarter, we made significant progress toward the commercialization of Northera(TM) (droxidopa) for the treatment ... [Published Individual.com - May 01 2013]
First reported Apr 08 2013 - Updated Apr 08 2013 - 1 reports

Is Chelsea Therapeutics A Buy After Skyrocketing Up Over 150%?

ByC.R. Jackson: Chelsea Therapeutics International Ltd. ( CHTP ) is currently pursuing U.S. Food and Drug Administration (FDA) approval for Northera (droxidopa) , a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 08 2013]
First reported Mar 27 2013 - Updated Mar 27 2013 - 1 reports

Chelsea Therapeutics Rally — Speculation or Desperation?

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is rallying on Wednesday after a report in Seeking Alpha called its Northera, a treatment for symptomatic neurogenic hypotension in... ... [Published 24/7 Wall St. - Mar 27 2013]
First reported Mar 27 2013 - Updated Mar 27 2013 - 1 reports

Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Here

By Shane Blackmon : On February 20, 2013 , Chelsea Therapeutics ( CHTP ) was given new life. The company received guidance from the FDA that its drug, Northera, could be resubmitted for approval based on the company's "Study 306B" data. Shares jumped ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 27 2013]
First reported Feb 20 2013 - Updated Feb 21 2013 - 2 reports

Chelsea Therapeutics International's CEO Discusses Chelsea Therapeutics Receives FDA Guidance for Northera (TM) (Droxidopa) NDA Resubmission With Study 306B Conference (Transcript)

Chelsea Therapeutics International Ltd. ( CHTP ) Chelsea Therapeutics International Receives FDA Guidance for Northera ( TM ) (Droxidopa) NDA Resubmission With Study 306B Conference Call February 20, 2013, 09:00 am ET Executives David Pitts - ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 20 2013]
First reported Feb 20 2013 - Updated Feb 20 2013 - 1 reports
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd

4 Healthcare Stock Stories Demanding Investor Focus

Celgene Corporation ( NASDAQ:CELG ): Current price $101.03 The company reported Wednesday that it has entered into an accelerated share repurchase arrangement with an investment bank so as to buy back a total of $600 million of its common stock. The plan ... [Published Wall St. Cheat Sheet - Feb 20 2013]
First reported Dec 06 2012 - Updated Dec 06 2012 - 1 reports

Investors Kick Chelsea After It Trips On Its Northera Data Again

By EP Vantage : Chelsea Therapeutics ( CHTP ) started 2012 as a fairly well-capitalised company as one-product groups working in CNS go, but will probably exit the year among the smallest of the small, and with little hope of getting the hypotension ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 06 2012]
First reported Dec 05 2012 - Updated Dec 05 2012 - 1 reports

Chelsea Therapeutics Still Alive: 306b Trial Supports Northera Efficacy And Safety

ByPropThink: Chelsea Therapeutics ( CHTP ) released preliminary results for its Phase III clinical study, called 306b, which evaluated the efficacy and safety of Northera, the company's drug candidate for symptomatic neurogenic orthostatic hypotension ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 05 2012]
First reported Dec 04 2012 - Updated Dec 04 2012 - 1 reports

Chelsea Therapeutics Still Has Room To Grow

ByElias Simpson: Last Friday, Nov. 30, on an otherwise average day for the market, Chelsea Therapeutics International ( CHTP ) looked more like a tidal surge than a stock chart. It got busy early, smashing through the 200 day moving average, and closed ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 04 2012]

Quotes

...Hypotension, a debilitating orphan condition that is greatly in need of alternative therapies," said Joseph G Oliveto, Interim CEO of Chelsea. "Our team has navigated through the significant challenges of showing a symptomatic benefit in this difficult to treat disease state, and now, with updated guidance from the U S FoodFood and Drug Administration, we have a regulatory path forward toward review and potential approval this year. We remain focused on resubmission of a New Drug Application for Northera in NOH."
Chelsea Therapeutics Reports First Quarter 2013 Financial Results [Published Individual.com - May 01 2013]
...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."
XXIA, EXAR, EPIQ, CPTS, CHTP, UNXL Expected To Be Up After Next Earnings Releases [Published Individual.com - Apr 29 2013]
...Results of the latest Phase III trial (the "306b trial) reported in early December were positive, but previously, the FDA gave guidance that results of this trial as well as several other Phase III trials (" 301, '302, and '306a) would not be enough to obtain approval, despite a positive recommendation by an FDA Panel last February...
FDA Changes Stance, Favors NDA Resubmission For CHTP's Northera [Published Healthcare Sector and Stocks Analysis from Seek... - Feb 20 2013]
If you require information regarding today's European corporate news please refer to the RANsquawk "EU Equity Opening News' sheet or visit www.RANsquawk.com. "
US EQUITIES OPENING HEADLINES INCLUDING: Covidien completes patient enrolment in Iliac stent clin ... [Published Proactiveinvestors United Kingdom RSS feed - Feb 20 2013]

More Content

All (22) | News (9) | Reports (7) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Chelsea Therapeutics International Ltd. (CHTP) ... [Published Live-PR.com - 5 hours ago]
Chelsea Therapeutics to Present at the 38th Ann... [Published Yahoo! Finance - May 22 2013]
Chelsea Therapeutics to Present at the 38th Ann... [Published Equities.com - May 22 2013]
Chelsea Therapeutics to Present at the 38th Ann... [Published Interest!ALERT - May 22 2013]
Chelsea Therapeutics Reports First Quarter 2013... [Published Individual.com - May 01 2013]
XXIA, EXAR, EPIQ, CPTS, CHTP, UNXL Expected To ... [Published Individual.com - Apr 29 2013]
Chelsea Therapeutics, Inc. to Present at the 12... [Published BioSpace - Apr 24 2013]
Is Chelsea Therapeutics A Buy After Skyrocketin... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 08 2013]
Why Starbucks is a Screaming Buy and 3 Other Ho... [Published Wall St. Cheat Sheet - Mar 27 2013]
Chelsea Therapeutics Rally — Speculation or Des... [Published 24/7 Wall St. - Mar 27 2013]
Chelsea Therapeutics: A Shoe-In For FDA Approva... [Published Healthcare Sector and Stocks Analysis from Seek ... - Mar 27 2013]
Chelsea Therapeutics Announces Presentation of ... [Published GlobeNewswire: Acquisitions News - Mar 19 2013]
4 Healthcare Stock Stories Demanding Investor F... [Published Wall St. Cheat Sheet - Feb 20 2013]
Chelsea Therapeutics International's CEO Discus... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 20 2013]
FDA Changes Stance, Favors NDA Resubmission For... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 20 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Covidi... [Published Proactiveinvestors United Kingdom RSS feed - Feb 20 2013]
Chelsea Therapeutics Receives FDA Guidance for ... [Published GlobeNewswire: Acquisitions News - Feb 20 2013]
Investors Kick Chelsea After It Trips On Its No... [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 06 2012]
Chelsea Therapeutics Still Alive: 306b Trial Su... [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 05 2012]
Chelsea Therapeutics Announces Northera(TM) (Dr... [Published GlobeNewswire: Advertising News - Dec 04 2012]
Chelsea Therapeutics Still Has Room To Grow [Published Healthcare Sector and Stocks Analysis from Seek ... - Dec 04 2012]
Chelsea Therapeutics to Present at the 14th Ann... [Published GlobeNewswire - Sep 04 2012]
1
In Focus
  •  
David Pitts, Jake King, Henry Roth, [more]
  •  
Chelsea Therapeutics International, Deutsche Bank AG, Carolina Group Incorporated, [more]
  •  
American Academy of Neurology, FDA Food & Drug Administration, Center for Drug Evaluation and Research, [more]
  •  
Droxidopa, primary endpoint, Parkinson's Disease, [more]
  •  
Viread, Lincoln MKS, Ford Taurus, [more]
  •  
Boston (Massachusetts, United States), San Diego (California, United States), New York City, [more]
  •  
United States, China, Japan, [more]
  •  
Diseases, Research & Development, Health Care, [more]
  •  
IT, Banking & Financial Services, Health, [more]
Healthcare Sector and Stocks Analysis from Seek..., GlobeNewswire: Acquisitions News, Individual.com, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Why Starbucks is a Screaming Buy and 3 Other Ho... [Published Wall St. Cheat Sheet - Mar 27 2013]
OptionMonster’s Jon Najarian is calling Starbucks ( NASDAQ:SBUX ) a screaming Buy because the price of Arabica coffee beans, a key input, have halved after reaching a peak in May of 2011. Pointing out that coffee prices per cup at the coffee chain ...
Chelsea Therapeutics Rally — Speculation or Des... [Published 24/7 Wall St. - Mar 27 2013]
Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is rallying on Wednesday after a report in Seeking Alpha called its Northera, a treatment for symptomatic neurogenic hypotension in... ...
4 Healthcare Stock Stories Demanding Investor F... [Published Wall St. Cheat Sheet - Feb 20 2013]
Celgene Corporation ( NASDAQ:CELG ): Current price $101.03 The company reported Wednesday that it has entered into an accelerated share repurchase arrangement with an investment bank so as to buy back a total of $600 million of its common stock. The plan ...
1

Press Releases

sort by: Date | Relevance
Chelsea Therapeutics Announces Presentation of ... [Published GlobeNewswire: Acquisitions News - Mar 19 2013]
Chelsea Therapeutics Receives FDA Guidance for ... [Published GlobeNewswire: Acquisitions News - Feb 20 2013]
Chelsea Therapeutics Announces Northera(TM) (Dr... [Published GlobeNewswire: Advertising News - Dec 04 2012]
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.